Wex Pharmaceuticals Inc. Enrolls in Korea as Part of the Multinational Phase 2B Clinical Trial Evaluating the Efficacy and Safety of Halneuron® in the Treatment of Chemotherapy-Induced Neuropathic Pain
VANCOUVER, BC — WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that the first patient in Korea has been enrolled… Read More




